Mereo Biopharma Group PLC
NASDAQ:MREO
Mereo Biopharma Group PLC
NASDAQ:MREO
Price:
3.1 USD
2.99%
Updated:
May 9, 2024
P/E
Price to Earnings
Price to Earnings
-13.4
Current
-3.3
Median
26.8
Industry
Lower
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-13.4
Market Cap
/
434.8m
Net Income
-26.1m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| UK |
|
Mereo Biopharma Group PLC
NASDAQ:MREO
|
434.8m USD | -13.4 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
283.6B USD | 58.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.1B USD | 44.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.9B USD | 29.8 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.8B USD | 27.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.8B AUD | 35.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.8B USD | 166.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
47.5B USD | -8 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.2B USD | 27.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.3T KRW | 73.4 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-11.5
2-Years Forward
P/E
-47.3
3-Years Forward
P/E
-12.2
You don't have any saved screeners yet
